Sun Pharma's Winlevi Cream Approved for Acne Treatment in Australia

19 Mar 2024 , 12:10 PM

Sun Pharmaceutical Industries Ltd announced that the Australian Therapeutic Goods Administration (TGA) has approved its clascoterone cream, Winlevi, for treating acne vulgaris in patients aged 12 and above.

Winlevi is set to be launched in Australia starting from June 2024, according to a regulatory filing made on March 19.

Hellen de Kloet, Business Head of Western Europe, Australia, and New Zealand at Sun Pharma, highlighted Winlevi’s innovative mechanism of action, expressing excitement about its addition to the company’s dermatology portfolio in Australia.

Diana Harbort, President of the Dermatology Division of Cosmo, Sun Pharma’s partner, expressed satisfaction at Winlevi’s approval, emphasizing the joint mission to enhance the lives of patients with skin conditions.

For feedback and suggestions, write to us at [e-mail]